• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Advancing Healthcare Solutions: Harnessing Collaborative Business Models for Oncology


Unique approaches are needed to bring solutions to fighting cancer and bacterial-resistant infections.

Sandra Von Meier

Sandra Von Meier
Head of business development

In the pharmaceutical landscape, the lack of effective, curative therapies, particularly in critical areas such as cancer treatment,1 underscores the urgent need for innovative solutions. The industry's relentless pursuit of profit often results in a nearsighted focus on blockbuster drugs, leaving niche treatments and rare diseases on the sidelines. This narrow prioritization has contributed to a scarcity of essential medications, leaving patients vulnerable and healthcare providers scrambling for alternatives. These shortages have far-reaching consequences, impeding patient care, stretching already strained resources, and eroding trust in the pharmaceutical establishment.

In response to these challenges, Debiopharm perceives the need for a unique approach to bring promising solutions for fighting cancer and bacterial-resistant infections to fruition. This recognition propels an unwavering commitment to adopting innovative strategies in drug development, exemplifying a willingness to explore new avenues and collaborate with diverse stakeholders to address the pressing needs of patients.

Collaboration: The Cornerstone of Successful Drug Development Ventures

Drug development is characterized2 by strategic collaboration, rigorous selection of promising molecules, and a nuanced licensing strategy. This model emphasizes the effectiveness of leveraging diverse partnerships to accelerate the pace of discovery and development, while expanding reach into emerging scientific frontiers. Many recognize that startups, universities, and researchers around the world hold a wealth of expertise and breakthrough research, but often lack the resources and reach to drive innovation forward. When large pharmaceutical industry companies forge the right partnerships, they can leverage complementary strengths and capabilities and collaborate to help companies navigate challenges more efficiently and bring new therapies to market at an accelerated rate. This collaborative synergy not only streamlines drug development, but also enhances its effectiveness, ultimately benefiting patients by delivering treatments more swiftly and effectively.

Furthermore, strategic collaboration enables companies to expand their reach into emerging scientific frontiers. By collaborating with partners across different disciplines and geographies, organizations gain access to cutting-edge research and technologies that may not be available otherwise. This cross-pollination of ideas and expertise keeps companies at the forefront of scientific advancements, driving innovation and pushing the boundaries of what's achievable in drug development.

Strategic Licensing: Maximizing Impact in Drug Development

A nuanced licensing strategy is essential for maximizing the impact and efficacy of innovative therapies in drug development. By strategically in-licensing promising compounds, pharmaceutical companies gain access to a diverse array of potential treatments that align with their therapeutic focus areas and strategic objectives. This alignment is crucial in maximizing the relevance of the drug portfolio, ultimately enhancing patient outcomes.

These compound libraries can sometimes include competing molecules, requiring an elimination process at some point during development. However, when pivoting to a more specialized collaborative approach, researchers and small startups can benefit from a narrower focus on their programs to determine the drug’s potential both in the initial stages and through the expanding phases of development, improving the chances that innovative medicines reach the market. The careful selection of in-licensing opportunities enables companies to capitalize on emerging trends and scientific advancements3 in specific therapeutic areas. By identifying and acquiring compounds with high therapeutic potential, companies can bolster their pipeline and maintain a competitive edge in the rapidly evolving pharmaceutical landscape.

Equally important is the thoughtful approach to out-licensing partnerships, which are essential for maximizing the potential of innovative therapies. By partnering with commercialization organizations capable of leveraging their global distribution networks and resources, pharmaceutical companies can ensure that their therapies reach patients worldwide in a timely and efficient manner. These strategic partnerships not only facilitate access to new markets but also accelerate the commercialization process, therefore benefiting patients by increasing access to life-saving treatments on a global scale.

Empowering Patient-Centric Innovation Through Digital Transformation

In the dynamic landscape of pharmaceuticals, digital transformation stands as a beacon of progress, catalyzing innovation and driving improvements in patient quality of life (QoL) throughout the drug development journey. At the heart of this transformation lies a steadfast commitment to patients, underscoring the industry's mission to enhance their lives and well-being.

The fusion of technology and pharmaceuticals has ushered in a new era of possibilities,4 accelerating drug discovery, development, and treatment experiences for patients. By harnessing the potential of technology, pharmaceutical companies are witnessing remarkable advancements in improving patient outcomes and QoL. It is imperative to identify and support technologies that offer proven, measurable impacts on patient well-being, aligning with the industry's core mission.

Debiopharm's digital transformation journey embodies this patient-centric ethos, with objectives focused on conducting more research with slightly more resources and reducing cycle times in the drug development process. Through significant investments in ten digital transformation projects, ranging from building a robust Data Fabric to leveraging advanced analytics and AI in early development, our mission is to pioneer a multifaceted approach to innovation. Digital transformation efforts encompass incremental process innovations automating business processes, as well as disruptive innovations harnessing the power of AI. Internal development of digital solutions is complemented by external collaborations with partners and companies within Debiopharm's portfolio of digital investments. The overarching goal is to facilitate and expedite drug development by leveraging predictive analytics and AI models to increase the probability of success (POS) for future drug candidates.

Digital health investment and transformation facilitate the integration of cutting-edge technologies, such as artificial intelligence and data analytics into drug discovery and development workflows. By leveraging these technologies, companies can streamline processes, identify biomarkers more accurately, and optimize clinical trial designs, accelerating the delivery of life-saving therapies to patients. In addition, effective partnerships in the digital health space enable pharmaceutical companies to access innovative technologies and solutions that complement their drug development efforts. Strategic decision-making ensures that investments are aligned with therapeutic focus areas and strategic objectives, maximizing the potential for impactful innovation and patient benefit.

Ultimately, this collaborative, strategic, and digitally enabled approach serves as a catalyst for innovation, driving advancements that have the potential to transform patient care and improve outcomes worldwide. By harnessing the power of effective partnerships, strategic decision-making, and digital transformation, pharmaceutical companies can usher in a new era of healthcare innovation and progress, ensuring that patients receive the life-changing therapies they need, when they need them.

Sandra Von Meier is head of business development at Debiopharm.


  1. Kim, Shi En. Why There’s a Serious Cancer Drug Shortage, and How to Fix It. Scientific American. September 18, 2023. https://www.scientificamerican.com/article/why-theres-a-serious-cancer-drug-shortage-and-how-to-fix-it/
  2. Mohs, Richard; Greig, Nigel. Drug Discovery and Development: Role of Basic Biological Research. National Library of Medicine. November 11, 2017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725284/
  3. Kim, Yu Chul. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. National Library of Medicine. July 10, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385763/
  4. Panderi, Irene. Challenges and Opportunities of Implementing Data Fusion in Process Analytical Technology–A Review. July 28, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369811/
Related Videos